These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23318416)

  • 1. Claudin-1 as a promoter of EMT in hepatocellular carcinoma.
    Stebbing J; Filipović A; Giamas G
    Oncogene; 2013 Oct; 32(41):4871-2. PubMed ID: 23318416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells.
    Suh Y; Yoon CH; Kim RK; Lim EJ; Oh YS; Hwang SG; An S; Yoon G; Gye MC; Yi JM; Kim MJ; Lee SJ
    Oncogene; 2013 Oct; 32(41):4873-82. PubMed ID: 23160379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells.
    Yoon CH; Kim MJ; Park MJ; Park IC; Hwang SG; An S; Choi YH; Yoon G; Lee SJ
    J Biol Chem; 2010 Jan; 285(1):226-33. PubMed ID: 19897486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pancreatic cancer.
    Kyuno D; Kojima T; Yamaguchi H; Ito T; Kimura Y; Imamura M; Takasawa A; Murata M; Tanaka S; Hirata K; Sawada N
    Carcinogenesis; 2013 Jun; 34(6):1232-43. PubMed ID: 23389293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Claudin-1 promotes TNF-α-induced epithelial-mesenchymal transition and migration in colorectal adenocarcinoma cells.
    Bhat AA; Ahmad R; Uppada SB; Singh AB; Dhawan P
    Exp Cell Res; 2016 Nov; 349(1):119-127. PubMed ID: 27742576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Claudins and hepatocellular carcinoma.
    Wang W; Zhou Y; Li W; Quan C; Li Y
    Biomed Pharmacother; 2024 Feb; 171():116109. PubMed ID: 38185042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NEIL3 promotes hepatoma epithelial-mesenchymal transition by activating the BRAF/MEK/ERK/TWIST signaling pathway.
    Lai HH; Hung LY; Yen CJ; Hung HC; Chen RY; Ku YC; Lo HT; Tsai HW; Lee YP; Yang TH; Chen YY; Huang YS; Huang W
    J Pathol; 2022 Dec; 258(4):339-352. PubMed ID: 36181299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways.
    Bao L; Yan Y; Xu C; Ji W; Shen S; Xu G; Zeng Y; Sun B; Qian H; Chen L; Wu M; Su C; Chen J
    Cancer Lett; 2013 Sep; 337(2):226-36. PubMed ID: 23684551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
    Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
    Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.
    Ogunwobi OO; Liu C
    Clin Exp Metastasis; 2011 Dec; 28(8):721-31. PubMed ID: 21744257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival.
    Bouchagier KA; Assimakopoulos SF; Karavias DD; Maroulis I; Tzelepi V; Kalofonos H; Karavias DD; Kardamakis D; Scopa CD; Tsamandas AC
    In Vivo; 2014; 28(3):315-26. PubMed ID: 24815833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cPLA2α activates PI3K/AKT and inhibits Smad2/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells.
    Fu H; He Y; Qi L; Chen L; Luo Y; Chen L; Li Y; Zhang N; Guo H
    Cancer Lett; 2017 Sep; 403():260-270. PubMed ID: 28649002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DA-Raf-Mediated Suppression of the Ras--ERK Pathway Is Essential for TGF-β1-Induced Epithelial-Mesenchymal Transition in Alveolar Epithelial Type 2 Cells.
    Watanabe-Takano H; Takano K; Hatano M; Tokuhisa T; Endo T
    PLoS One; 2015; 10(5):e0127888. PubMed ID: 25996975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
    Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
    Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
    Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
    J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Claudin-7 inhibits human lung cancer cell migration and invasion through ERK/MAPK signaling pathway.
    Lu Z; Ding L; Hong H; Hoggard J; Lu Q; Chen YH
    Exp Cell Res; 2011 Aug; 317(13):1935-46. PubMed ID: 21641901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor modulates claudins and tight junctional functions in ovarian cancer cell lines.
    Ogawa M; Kojima T; Someya M; Nomura K; Takasawa A; Murata M; Tanaka S; Saito T; Sawada N
    Histochem Cell Biol; 2012 Aug; 138(2):323-38. PubMed ID: 22544349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic Raf-1 regulates epithelial to mesenchymal transition via distinct signal transduction pathways in an immortalized mouse hepatic cell line.
    Lan M; Kojima T; Osanai M; Chiba H; Sawada N
    Carcinogenesis; 2004 Dec; 25(12):2385-95. PubMed ID: 15308585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
    Alsuliman A; Colak D; Al-Harazi O; Fitwi H; Tulbah A; Al-Tweigeri T; Al-Alwan M; Ghebeh H
    Mol Cancer; 2015 Aug; 14():149. PubMed ID: 26245467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA
    Tong Y; Wang M; Dai Y; Bao D; Zhang J; Pan H
    Hum Gene Ther Clin Dev; 2019 Sep; 30(3):129-141. PubMed ID: 30963785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.